- Home
- REGN vs FDX Comparison
REGN vs FDX Comparison
Compare REGN & FDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REGN | FDX |
|---|---|---|
| Founded | 1988 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Air Freight/Delivery Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.8B | 76.9B |
| IPO Year | 1995 | 1997 |
Fundamental Metrics
Financial Performance| Metric | REGN | FDX |
|---|---|---|
| Price | $827.26 | $322.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 25 | 21 |
| Target Price | ★ $830.16 | $376.67 |
| AVG Volume (30 Days) | 565.1K | ★ 1.4M |
| Earning Date | 04-29-2026 | 03-19-2026 |
| Dividend Yield | 0.55% | ★ 1.49% |
| EPS Growth | 8.19 | ★ 10.35 |
| EPS | ★ 18.95 | 18.55 |
| Revenue | $5,872,227,000.00 | ★ $65,450,000,000.00 |
| Revenue This Year | $12.45 | $7.43 |
| Revenue Next Year | $10.13 | $4.96 |
| P/E Ratio | $44.35 | ★ $17.43 |
| Revenue Growth | ★ 20.82 | N/A |
| 52 Week Low | $541.00 | $222.06 |
| 52 Week High | $859.34 | $413.87 |
Technical Indicators
Market Signals| Indicator | REGN | FDX |
|---|---|---|
| Relative Strength Index (RSI) | 65.31 | 48.28 |
| Support Level | $732.04 | $321.69 |
| Resistance Level | $847.00 | $342.63 |
| Average True Range (ATR) | 19.34 | 7.93 |
| MACD | -3.02 | -1.28 |
| Stochastic Oscillator | 76.33 | 31.54 |
Price Performance
Historical ComparisonAbout REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
About FDX FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. Following the June 2026 spinoff of FedEx Freight (less-than-truckload shipping), the firm's Federal Express segment-which houses the core package delivery operations-makes up more than 95% of total revenue (previously 87%). The remainder stems from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016, boosting its presence across Europe. TNT was previously the fourth-largest global parcel delivery provider.